Compatibility Studies

The goal of drug-excipient Compatibility studies is to detect, measure, and forecast possible interactions (physical or chemical), as well as the influence of these interactions on the manufacturability, quality, ad performance of the final therapeutic product. Excipients are chemicals that are included in dosage forms together with the active pharmaceutical ingredient (API). The majority of excipients have no direct pharmacological effect; however, they are useful for simplifying administration, regulating active component release, and stabilising API against degradation. However, improper excipients might cause accidental and/or unanticipated impacts on the chemical composition, stability, and bioavailability of the API, and hence their medicinal effectiveness and safety. In the development stage of all dosage forms, drug-excipient compatibility studies are a crucial step in finding interactions between prospective formulation excipients and the API.
 

Committee Members
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami, United States
Speaker at Drug Delivery Events - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Pharmaceutical Conference - Axel H Schonthal

Axel H Schonthal

University of Southern California, United States
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
PDDS 2026 Speakers
Speaker at Pharmaceutical Conference - Madhav Bhatia

Madhav Bhatia

University of Otago, New Zealand
Speaker at Pharma Conferences - Luis Jesus Villarreal Gomez

Luis Jesus Villarreal Gomez

Universidad Autónoma de Baja California, Mexico
Speaker at Pharma Conferences - Saad Tayyab

Saad Tayyab

UCSI University, Malaysia
Speaker at Drug Delivery Events - Anil Pareek

Anil Pareek

Anand Pharmacy College, India
Speaker at Pharmaceutical Conference - Lan Wang

Lan Wang

Paretor LLC, United States
Speaker at Pharmaceutical Conference - Helen Cho

Helen Cho

Samyang Biopharm Corporation, Korea, Republic of

Submit your abstract Today

Youtube
Watsapp